JP2022530471A5 - - Google Patents

Info

Publication number
JP2022530471A5
JP2022530471A5 JP2021563360A JP2021563360A JP2022530471A5 JP 2022530471 A5 JP2022530471 A5 JP 2022530471A5 JP 2021563360 A JP2021563360 A JP 2021563360A JP 2021563360 A JP2021563360 A JP 2021563360A JP 2022530471 A5 JP2022530471 A5 JP 2022530471A5
Authority
JP
Japan
Prior art keywords
composition according
neuroprotective compound
compound
neurodegeneration
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563360A
Other languages
English (en)
Japanese (ja)
Other versions
JP7633179B2 (ja
JP2022530471A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2020/050547 external-priority patent/WO2020215164A1/en
Publication of JP2022530471A publication Critical patent/JP2022530471A/ja
Publication of JP2022530471A5 publication Critical patent/JP2022530471A5/ja
Application granted granted Critical
Publication of JP7633179B2 publication Critical patent/JP7633179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563360A 2019-04-24 2020-04-24 神経保護のためのカンナビノイドの組成物及び使用方法 Active JP7633179B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
US62/838,216 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (3)

Publication Number Publication Date
JP2022530471A JP2022530471A (ja) 2022-06-29
JP2022530471A5 true JP2022530471A5 (cg-RX-API-DMAC7.html) 2023-05-02
JP7633179B2 JP7633179B2 (ja) 2025-02-19

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563360A Active JP7633179B2 (ja) 2019-04-24 2020-04-24 神経保護のためのカンナビノイドの組成物及び使用方法

Country Status (11)

Country Link
US (1) US20230043428A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958856A4 (cg-RX-API-DMAC7.html)
JP (1) JP7633179B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220080045A (cg-RX-API-DMAC7.html)
CN (1) CN114007603A (cg-RX-API-DMAC7.html)
AU (1) AU2020261515B2 (cg-RX-API-DMAC7.html)
CA (1) CA3134764A1 (cg-RX-API-DMAC7.html)
IL (1) IL287536B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021012960A (cg-RX-API-DMAC7.html)
SG (1) SG11202111809XA (cg-RX-API-DMAC7.html)
WO (1) WO2020215164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
US20240139272A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism
AU2024206205A1 (en) * 2023-01-04 2025-07-17 Florascience Inc. Cannabinoids for use in the treatment of a neurodegenerative disease or condition
IL327899A (en) * 2023-10-23 2026-06-01 Inmed Pharmaceuticals Inc Compositions and methods for use of cannabinol compounds in neuroprotection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
BR112013012468A2 (pt) * 2010-11-18 2016-09-06 Pier Pharmaceuticals método de tratar um indivíduo com um distúrbio sensível a canabinóide, de estabelecer uma dose ideal, de tratar um indivíduo com um distúrbio de apneia do sono, e, kit
MX2017005277A (es) * 2014-10-21 2018-01-11 United Cannabis Corp Extractos de cannabis y métodos de preparación y uso de la misma.
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3261629A4 (en) * 2015-02-27 2018-12-05 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20160282371A1 (en) * 2015-03-28 2016-09-29 Quantalytical Labs Inc. Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
JP7225103B2 (ja) * 2016-10-11 2023-02-20 ジービーエス グローバル バイオファーマ,インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
CN110997006A (zh) * 2017-05-08 2020-04-10 因美制药公司 眼部药物递送制剂
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same

Similar Documents

Publication Publication Date Title
TW401300B (en) Antiallergic composition for ophthalmic or nasal use
TWI773706B (zh) 用於眼用活性藥物成分輸送的固體環糊精複合物之製備
TWI618539B (zh) 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
CN100453066C (zh) 利用结膜下储存库的药物释放系统
JP7716996B2 (ja) 薬剤を含む水性組成物のpHを安定化させるための方法
AU2009329024A1 (en) Curcuminoids and its metabolites for the application in ocular diseases
SA516380321B1 (ar) مستحضرات للعين لتوصيل الدواء إلى الجزء الخلفي من العين
WO2003070219A1 (en) Drug delivery system for the subconjunctival administration of fine grains
JP2021525710A (ja) 眼充血を治療するための組成物およびそれを用いて眼充血を治療するための方法
JP2018521117A (ja) シクロスポリンa/シクロデキストリンナノ粒子の形成
KR102555091B1 (ko) 약물 전달 및 전안부 보호를 위한 안구용 제제
CN104661682A (zh) 水性液剂
JP2021091697A (ja) 水性点眼点鼻用組成物
López-Cano et al. New trends towards glaucoma treatment: Topical osmoprotective microemulsions loaded with latanoprost
JP2022547231A5 (cg-RX-API-DMAC7.html)
KR20210158355A (ko) 디쿠아포솔을 포함하는 점안 조성물
KR20100051811A (ko) 눈에 수용체 티로신 키나제 저해(rtki) 화합물을 전달하기 위한 약제학적 제제
US12576126B2 (en) Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof
FR3077984A1 (fr) Composition multiusage de torasemide
TW201705956A (zh) 唑系抗真菌藥之對眼瞼皮膚的投與
RU2521337C1 (ru) Фармацевтическая композиция для лечения заболеваний глаз, связанных с нарушением метаболизма в тканях глаза и воспалительным поражением тканей глаза
JP2022540572A (ja) 眼疾患を治療するための組成物および方法
TWI801053B (zh) 眼用組合物
CN104997729A (zh) 含磺丁基醚-β-环糊精的普拉洛芬滴眼液及其制备方法
TW202345853A (zh) 無防腐劑的眼科藥物乳劑及其應用